Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms [EARLY_Phase 1]
An early-phase study of CAR 70-BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms, with recruitment not yet started.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation [EARLY_Phase 1]
This early-phase 1 clinical trial investigates CAR19BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms and lymphomas/leukemia…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
A multicenter prospective study aims to predict response to selinexor-based therapy in relapsed/refractory multiple myeloma and is currently…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Study of CAR-T Therapy in Older Patients
A clinical trial update describing a CAR-T therapy study enrolling older adults with B-cell lymphomas and multiple myeloma, currently recrui…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) [Phase 1]
Phase 1 study evaluating NT-I7 (recombinant human interleukin-7) in relapsed/refractory multiple myeloma patients who previously received BC…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy [Phase 3]
This is a Phase 3 clinical trial update evaluating lenalidomide plus subcutaneous daratumumab versus lenalidomide plus dexamethasone in frai…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma [Phase 3]
A Phase 3 study evaluating Gammagard Liquid (intravenous immunoglobulin 10%) to prevent infections in adults with multiple myeloma is curren…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) [Phase 1, Phase 2]
Clinical trial DURGA-1 evaluating AZD0120 in relapsed/refractory multiple myeloma is in Phase 1/Phase 2 and currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
A clinical trial update on Daratumumab-Pomalidomide-Dexamethasone (Dara-PD) for patients with first-relapse multiple myeloma; the study is c…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical update on a Phase 1/Phase 2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma; the trial is currently…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial sponsored by Hoffmann-La Roche to evaluate multiple treatments for adults with multiple myeloma; the stu…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for Eque-cel in relapsed/refractory multiple myeloma; the study status is NOT_YET_RECRUITING.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients [NA]
A University of Chicago-sponsored study is evaluating measurable residual disease in multiple myeloma patients, with the trial currently act…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: ATRA and Carfilzomib in Plasma Cell Myeloma Patients [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating the combination of all-trans retinoic acid (ATRA) and carfilzomib in patie…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial [Phase 3]
A Phase 3 study named EQUATE is testing a combination therapy for adults with newly diagnosed multiple myeloma, and the trial is currently r…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients [Phase 3]
This entry describes a Phase 3 trial comparing elranatamab plus lenalidomide consolidation and/or elranatamab maintenance versus standard of…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant [Phase 2]
Phase 2 trial investigating whether Ide-cel (idecabtagene vicleucel) can be manufactured from patients with multiple myeloma who have previo…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer [Phase 2]
TAPUR is a Phase 2 study testing FDA-approved cancer drugs that target specific tumor gene abnormalities in patients with advanced cancers; …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) [Phase 1]
A Phase 1 study evaluating ISB 2001 in relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Survivors Uniting for Remote Guided Exercise [NA]
Clinical trial update from Colorado State University about a remote guided exercise program for cancer survivors; the study is currently rec…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial is evaluating the combination of belantamab mafodotin and lenalidomide in patients with multiple myeloma who remain…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) [Phase 1]
Phase I, open-label, multicenter study to evaluate safety, tolerability, cellular kinetics, immunogenicity, pharmacodynamics, and preliminar…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Hypofractionation (Radiation) Trial for Multiple Myeloma [Phase 1]
A Phase 1 clinical trial at the University of Chicago is evaluating hypofractionation radiation therapy for multiple myeloma and is currentl…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol [Phase 1, Phase 2]
A master protocol trial evaluating Isatuximab in combination with novel agents for relapsed/refractory multiple myeloma is in Phase 1/2 and …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
This is a Phase 1 clinical trial evaluating intravenous etentamig in combination with an oral CELMoD agent for adults with relapsed or refra…